Exclusive: Spot Bio launches with $40M to study mRNA therapy for muscular dystrophy
Spot Biosystems Launches with $40 Million Financing and World-First Non-Viral Delivery of Full-Length Dystrophin in Animal Models and Human Patients with DMD
Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy
mRNA Delivery of Gene Therapy using Extracellular Vesicles Produces Better Immune Response than AAV and LNP Delivery
Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity
Novel delivery system opens doors for mRNA therapy
Scientists develop novel mRNA delivery method using extracellular vesicles